tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate | 1290191-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate
• CAS: 1290191-85-3；1152113-30-8
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.281
• InChiKey: DUBXUUPBIKNFEA-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate 、 二碳酸二叔丁酯 以 甲醇 为溶剂， 以60 mg的产率得到(3R,4S)-1-tert-butoxycarbonyl-3-tert-butoxycabonylamino-4-methylpyrrolidine
  参考文献：
  名称：

  Stereoselective synthesis of (3R,4S)-3-amino-4-methyl pyrrolidine

  摘要：

  A stereoselective approach for the synthesis of (3R,4S)-3-amino-4-methyl pyrrolidine, a part of the structure of a quinoline antibacterial compound and the naphthyridine antitumor agent, is described. The key reaction is the one-pot reduction and regioselective cyclization of azidoditosyl derivative 9 to pyrrolidine 10. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.10.005
• 作为产物：
  描述：

  (3R,4S)-3-azido-1-tert-butoxycarbonyl-4-methylpyrrolidine 在 10% Pd/C 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  Stereoselective synthesis of (3R,4S)-3-amino-4-methyl pyrrolidine

  摘要：

  A stereoselective approach for the synthesis of (3R,4S)-3-amino-4-methyl pyrrolidine, a part of the structure of a quinoline antibacterial compound and the naphthyridine antitumor agent, is described. The key reaction is the one-pot reduction and regioselective cyclization of azidoditosyl derivative 9 to pyrrolidine 10. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.10.005

文献信息

• [EN] Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection<br/>[FR] NOUVEAUX COMPOSÉS PYRIDO[2,3-B]INDOLE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION BACTÉRIENNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018178041A1

  公开（公告）日：2018-10-04

  The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的新化合物，其中R1、R2、R3、R4、R5和R6如本文所述，以及它们的药用盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• [EN] KRAS G12D INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12D
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2022031678A1

  公开（公告）日：2022-02-10

  The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12D的化合物。具体而言，本发明涉及抑制KRas G12D活性的化合物，包括含有这些化合物的药物组合物以及使用方法。
• 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors
  申请人：Xue Chu-Biao

  公开号：US20090247474A1

  公开（公告）日：2009-10-01

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及公式I的3-氨基吡咯烷衍生物（其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y和X如本文所定义），其可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体的调节剂，更具体地作为CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可以结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并且可用于治疗与趋化因子，例如CCR2和/或CCR5活性相关的疾病，例如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• PEPTIDE DEFORMYLASE INHIBITORS
  申请人：Qin Donghui

  公开号：US20090306066A1

  公开（公告）日：2009-12-10

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，包含它们的组合物，这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面的使用。具体而言，本发明涉及式（I）的化合物：其中R1，R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1
  作者：Wenchao Lu、Yao Liu、Yang Gao、Qixiang Geng、Deepak Gurbani、Lianbo Li、Scott B. Ficarro、Cynthia J. Meyer、Dhiraj Sinha、Inchul You、Jason Tse、Zhixiang He、Wenzhi Ji、Jianwei Che、Audrey Y. Kim、Tengteng Yu、Kenneth Wen、Kenneth C. Anderson、Jarrod A. Marto、Kenneth D. Westover、Tinghu Zhang、Nathanael S. Gray

  DOI：10.1021/acs.jmedchem.2c01834

  日期：2023.3.9

  The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family, which includes JNK1–JNK3. Interestingly, JNK1 and JNK2 show opposing functions, with JNK2 activity favoring cell survival and JNK1 stimulating apoptosis. Isoform-selective small molecule inhibitors of JNK1 or JNK2 would be useful as pharmacological probes but have been difficult to develop due to

  c-Jun N 末端激酶 (JNK) 是丝裂原激活蛋白激酶 (MAPK) 家族的成员，该家族包括 JNK1–JNK3。有趣的是，JNK1 和 JNK2 显示出相反的功能，JNK2 活性有利于细胞存活，而 JNK1 则刺激细胞凋亡。 JNK1 或 JNK2 的异构体选择性小分子抑制剂可用作药理学探针，但由于其 ATP 结合口袋的相似性而难以开发。在这里，我们描述了共价抑制剂 YL5084 的发现，这是第一个对 JNK2 比 JNK1 显示选择性的抑制剂。我们证明，YL5084 与 JNK2 的 Cys116 形成共价键，与 JNK1 相比， K inact / K I高 20 倍，并与细胞中的 JNK2 结合。然而，YL5084 在多发性骨髓瘤细胞中表现出不依赖 JNK2 的抗增殖作用，表明在这种情况下存在其他相关靶点。因此，虽然尚未完全优化，但 YL5084 代表了 JNK2 选择性化学探针未来开发的有用化学起点。